Article successfully added.

CyFlow™ CD99 FITC

CyFlow™ CD99 FITC
Alternative Name: E2 , MIC2
Antibody: Yes
Antigen: CD99
Application: Flow cytometry
Clonality: monoclonal
Clone: 3B2/TA8
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: FITC
Isotype: IgG2a
Laser: Blue
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: AN564845

For Research Use Only

$235.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
HLDA Workshop HLDA VI—WS Code T 6T-097, BP 534 Quantity 100 tests Volume 0.4 mL... more
Close menu
CyFlow™ CD99 FITC

HLDA WorkshopHLDA VI—WS Code T 6T-097, BP 534
Quantity100 tests
Volume0.4 mL
ImmunogenHuman thymocytes
Background InformationCD99 is a ubiquitous transmembrane type I sialoglycoprotein of a unique and poorly characterized protein family. CD99 is heavily O-glycosylated and was described as a T cell costimulator and strong activator of integrin-mediated actin cytoskeleton assembly, promoting cell adhesion and homotypic aggregation, immediate arrest on an inflamed vascular endothelium, and cell migration through it. Ligation of CD99 under some conditions can lead to apoptosis. Originally, CD99 was described as a human thymus leukemia antigen, an Ewing´s sarcoma-specific membrane marker, and an adhesion molecule involved in spontaneous rosette formation of T cells with erythrocytes.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ, Baumruker T, Stöckl J, Ebner C, Knapp W, Pickl WF: CD99 engagement on human peripheral blood T cells results in TCR/CD3‑dependent cellular activation and allows for Th1‑restricted cytokine production. J Immunol. 1998 Nov 1; 161(9):4671‑8. < PMID: 9794396 > | Pickl WF, Pimentel-Muiños FX, Seed B: Lipid rafts and pseudotyping. J Virol. 2001 Aug; 75(15):7175‑83. < PMID: 11435598 > | Kish DD, Gorbachev AV, Fairchild RL: CD8+ T cells produce IL‑2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses. J Leukoc Biol. 2005 Sep; 78(3):725‑35. < PMID: 16000396 > | Kueng HJ, Leb VM, Haiderer D, Raposo G, Thery C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF: General strategy for decoration of enveloped viruses with functionally active lipid‑modified cytokines. J Virol. 2007 Aug; 81(16):8666‑76. < PMID: 17537846 > | Brémond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, Breittmayer JP, Gounon P, Gleeson PA, Bernard A, Bernard G: Regulation of HLA class I surface expression requires CD99 and p230/golgin‑245 interaction. Blood. 2009 Jan 8; 113(2):347‑57. < PMID: 18849489 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet